SPY457.40+6.90 1.53%
DIA346.61+6.15 1.81%
IXIC15,381.32+127.27 0.83%

Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $8

Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and lowers the price target from $10 to $8.

Benzinga · 11/11/2021 06:43
Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and lowers the price target from $10 to $8.